Novartis taps Euro for Elidel, Lamisil med ed

Share this article:

Novartis has tapped Euro RSCG Life to handle its global Elidel medical education business following a competitive pitch against several unknown agencies. The Havas network will also take on project work for Lamisil med ed.
The global medical education assignment for Novartis' dermatology franchise, including both Elidel and Lamisil, was previously handled by London-based Parthenon Medical Communications, a division of Boca Raton, Fla. publisher CRC Press' U.K. imprint, Parthenon Publishing.
Work on the accounts will target both primary care and specialty physicians, and will be handled out of Euro RSCG Life's London office and led by Cliff Wyatt, president, medical education Europe.
Euro RSCG Life, MM&M's Network of the Year for 2004, was named a preferred vendor on Novartis' global medical education business last year.

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.